Vtv Therapeutics Inc. · NASDAQ:VTVT
Vtv Therapeutics — Investor Presentation (March 2024)
16 slides from Vtv Therapeutics's investor presentation, Mar 5, 2024
Slide 1: Improving the Lives of Millions of Patients with Type 1 Diabetes
Improving the Lives of Millions of Patients with Type 1 Diabetes Nasdaq: VTVT
Slide 2: Forward-Looking Statements
THE STATEMENTS MADE IN THIS PRESENTATION AND THE ACCOMPANYING ORAL COMMENTARY MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING (I) THE DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVESTIGATIONAL AND MARKETED PRODUCTS
Slide 3: vTv Value Proposition
3vTv Therapeutics vTv Value Proposition • 1.6 million people in the US have type 1 diabetes Growing at a rate of 2.9% annually ~80% of patients fail to achieve adequate blood glucose control • Phase 3-ready asset in cadisegliatin – an adjunct therapy for T1D patients to improve glycemic control
Slide 4: Leadership Builds upon Decades of Life Sciences Expertise
Leadership Builds upon Decades of Life Sciences Expertise 4vTv Therapeutics Paul Sekhri President & CEO Carmen Valcarce, PhD Chief Scientific Officer Steven Tuch Chief Financial Officer Rich Nelson Head Corporate Development Martin Lafontaine Commercial Consultant Thomas Strack, MD Chief Medical Off
Slide 5: Key Recent Developments
5vTv Therapeutics • Successful $51 million PIPE investment to fund first Phase 3 trial • Building out team Hired Thomas Strack, Chief Medical Officer Additional staffing anticipated in first half of 2024 • Finalized plans for first Phase 3 clinical trial Protocol submitted to the FDA in Februar
Slide 6: Financing
6vTv Therapeutics • $51 million raised through the sale of a combination of common stock and prefunded warrants • Combined with cash on hand, the capital raised will fund the first Phase 3 clinical trial for cadisegliatin • Subject to certain conditions, investors can purchase up to an additional $3
Slide 7: References
7vTv Therapeutics 1. Cariou B, Fontaine P, Eschwege E, Lièvre M, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab. 2015 Apr;41(2):116-25 and Khunti K, Alsif
Slide 8: Cadisegliatin is the First Liver-Selective Glucokinase Activator to Reach Phase 3
Cadisegliatin is the First Liver-Selective Glucokinase Activator to Reach Phase 3 Pancreas Effect Lowers threshold for insulin production Triggers storage of glucose as glycogen Result Rapid decline in blood sugar levels: Induces Hypoglycemia Reduces elevated blood sugar levels; Glucose released whe
Slide 9: In Non-Diabetic People, the Liver Acts as a Reservoir for Glucose
In Non-Diabetic People, the Liver Acts as a Reservoir for Glucose with Insulin and Glucokinase being Key Gatekeepers Glucokinase When blood sugar is high Glucokinase, in presence of insulin, converts some glucose into glycogen for storage Insulin Glucose When blood sugar is low Glycogen reserves are
Slide 10: With Type 1 Diabetes, Glucokinase Activity Is Impaired
With Type 1 Diabetes and Only Low Levels of Insulin Reaching the Liver, Glucokinase Activity Is Impaired Glucokinase When blood sugar is high Glucokinase activity is diminished due to low insulin in the liver, reducing glycogen storage When blood sugar is low Insufficient glycogen reserves to mainta
Slide 11: Cadisegliatin Reactivates Innate Glucose-Regulating Capacity of the Liver
Cadisegliatin Reactivates Innate Glucose-Regulating Capacity of the Liver Even in the Absence of Increased Insulin Levels When blood sugar is high Glucokinase is activated despite lower insulin levels When blood sugar is low Glycogen reserves available to prevent hypoglycemia Portal Vein cadisegliat
Slide 12: Our SimpliciT1 Trial Showed Reductions In Both Hypoglycemia and HbA1c
12vTv Therapeutics Our SimpliciT1 Trial Showed Reductions In Both Hypoglycemia and HbA1c Trials sponsored in part by: Randomized, Double-Blind, Placebo Controlled 2-Part Study of ~100 patients. A total of 49 patients in the treatment groups received 800mg daily of cadisegliatin. Study Details: https
Slide 13: Clinical Development Plan: TTP399-302 Phase 3 Trial
Clinical Development Plan: TTP399-302 is the first Phase 3 trial to assess the efficacy of cadisegliatin in patients utilizing continuous glucose monitoring (CGM) 8-12 weeks Choice of endpoint, exposure & population criteria informed by specific FDA advice & published FDA clinical guidance Sc re en
Slide 14: Strong IP Protection for Cadisegliatin through 2041
Strong IP Protection for Cadisegliatin through 2041 Exclusivity Period* 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 Issued Proposed Product Cadisegliatin Formulation: Spray-Dried or Wet Granulation (Estimated Expiration 2-28-2034) Combo: Cadisegliat
Slide 15: Pipeline
PRODUCT PRE-CLINICAL PHASE I PHASE II PHASE III PARTNERS + REGIONS Cadisegliatin (TTP399) GK Activator TTP273 Oral GLP-1R Agonist HPP737 PDE4 Inhibitor Mavodelpar (HPP593) PPAR-𝛿𝛿 Agonist Azeliragon RAGE Antagonist HPP3033 Nrf2/Bach1 Modulator TTP-RA RAGE Antagonist vTv Partner vTv and Partner…
Slide 16: Conclusions
16vTv Therapeutics Conclusions
vTv Therapeutics — Investor Presentation (March 2024) on 6ix